Squarepoint’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Squarepoint’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-21,900	Closed	-$22.3K	–	5322
2024 Q4	$22.3K	Buy	+21,900	New	+$40K	﹤0.01%	4927

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Squarepoint's SGMO Position: Q3 2025 in Review

Squarepoint sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 625,034 shares — an estimated $338K sold.

Squarepoint first reported a position in SGMO in Q4 2015 and held it in 24 quarters. The position peaked at $2.29M in Q1 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

Squarepoint reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
Squarepoint sold 625,034 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $338K.
Squarepoint first reported a position in SANGAMO THERAPEUTICS INC in Q4 2015 and held it in 24 quarters.
Squarepoint's SANGAMO THERAPEUTICS INC position peaked at $2.29M in Q1 2018.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.